STOCK TITAN

[6-K] WORK Medical Technology Group LTD Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

WORK Medical Technology Group (WOK) consolidated its shares 100:1, effective October 21, 2025, to address Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and mitigate delisting risk. The company has until April 6, 2026 to regain compliance.

As of October 20, 2025, the company had 103,591,276 ordinary shares outstanding (95,998,776 Class A; 7,592,500 Class B). After the consolidation, there were approximately 1,035,913 ordinary shares outstanding (about 959,988 Class A; 75,925 Class B), subject to rounding up of fractional shares to whole shares.

The ticker remains “WOK,” and the Class A shares now trade under CUSIP G9767H117. Authorized capital increased to US$10,000,000, divided into 160,000,000 Class A ordinary shares of par value US$0.05 each and 40,000,000 Class B ordinary shares of par value US$0.05 each. Shareholders holding electronically did not need to take action.

WORK Medical Technology Group (WOK) ha consolidato le proprie azioni 100:1, con effetto dal 21 ottobre 2025, per soddisfare il requisito di prezzo minimo di Nasdaq ai sensi della Nasdaq Listing Rule 5550(a)(2) e mitigare il rischio di delisting. L’azienda ha tempo fino al 6 aprile 2026 per tornare a rispettare le norme.

Al 20 ottobre 2025, la società aveva 103.591.276 azioni ordinarie in circolazione (95.998.776 Classe A; 7.592.500 Classe B). Dopo la consolidazione, vi erano circa 1.035.913 azioni ordinarie in circolazione (circa 959.988 Classe A; 75.925 Classe B), soggette all’arrotondamento delle azioni frazionarie alle azioni intere.

Il ticker rimane “WOK” e le azioni Classe A ora sono negoziate sotto il CUSIP G9767H117. Il capitale autorizzato è aumentato a US$10.000.000, suddiviso in 160.000.000 azioni ordinarie Classe A dal valore nominale di US$0,05 ciascuna e 40.000.000 azioni ordinarie Classe B dal valore nominale di US$0,05 ciascuna. Gli azionisti tenuti in forma elettronica non hanno dovuto intraprendere alcuna azione.

Grupo de Tecnología Médica WORK (WOK) consolidó sus acciones 100:1, con efectos a partir del 21 de octubre de 2025, para cumplir con el requisito de precio mínimo de Nasdaq según la Regla de Listado 5550(a)(2) y mitigar el riesgo de salida de la lista. La empresa tiene hasta el 6 de abril de 2026 para volver a cumplir.

Al 20 de octubre de 2025, la compañía tenía 103.591.276 acciones ordinarias en circulación (95.998.776 Clase A; 7.592.500 Clase B). Después de la consolidación, había aproximadamente 1.035.913 acciones ordinarias en circulación (aproximadamente 959.988 Clase A; 75.925 Clase B), sujeto al redondeo de fracciones a acciones enteras.

El ticker sigue siendo “WOK”, y las acciones Clase A ahora se negocian bajo el CUSIP G9767H117. El capital autorizado aumentó a US$10,000,000, dividido en 160,000,000 de acciones ordinarias Clase A con valor nominal de US$0.05 cada una y 40,000,000 de acciones ordinarias Clase B con valor nominal de US$0.05 cada una. Los accionistas que mantenían electrónicamente no necesitaron tomar ninguna acción.

WORK Medical Technology Group(WOK)가 100:1로 주식 합병을 2025년 10월 21일부로 실행하여 나스닥의 5550(a)(2) 규정에 따른 최저 매매가 요건을 충족하고 상장폐지 위험을 완화했습니다. 회사는 규정을 다시 준수하기 위해 2026년 4월 6일까지의 기간이 있습니다.

2025년 10월 20일 현재 회사의 보통주 발행 주식 수는 103,591,276주였습니다(클래스 A 95,998,776주; 클래스 B 7,592,500주). 합병 후에는 대략 1,035,913주가 발행되어(대략 A 959,988주; B 75,925주), 소수점 주는 정수 주로 반올림될 수 있습니다.

티커는 여전히 “WOK”이며 클래스 A 주식은 이제 CUSIP G9767H117로 거래됩니다. 승인 자본은 미화 1,000만 달러로 증가했으며, 1억6천만 주의 클래스 A 보통주(표면가 US$0.05)와 4천만 주의 클래스 B 보통주(표면가 US$0.05)로 구성됩니다. 전자적으로 보유한 주주들은 아무 조치도 필요하지 않았습니다.

WORK Medical Technology Group (WOK) a consolidé ses actions en 100:1, avec effet au 21 octobre 2025, afin de répondre à l’exigence de prix d’introduction minimum de Nasdaq conformément à la règle Nasdaq Listing 5550(a)(2) et de réduire le risque de radiation. L’entreprise dispose jusqu’au 6 avril 2026 pour retrouver la conformité.

Au 20 octobre 2025, la société comptait 103 591 276 actions ordinaires en circulation (95 998 776 Classe A; 7 592 500 Classe B). Après la consolidation, il y avait environ 1 035 913 actions ordinaires en circulation (environ 959 988 Classe A; 75 925 Classe B), sous réserve de l’arrondi des fractions à des actions entières.

Le symbole boursier demeure «WOK», et les actions Classe A se négocient désormais sous le CUSIP G9767H117. Le capital autorisé a été porté à 10 000 000 USD, réparti en 160 000 000 d’actions ordinaires Classe A d’une valeur nominale de 0,05 USD chacune et 40 000 000 d’actions ordinaires Classe B d’une valeur nominale de 0,05 USD chacune. Les actionnaires détenant électroniquement n’avaient pas besoin d’agir.

WORK Medical Technology Group (WOK) hat seine Aktien im Verhältnis 100:1 zusammengelegt, mit Wirkung zum 21. Oktober 2025, um die Mindestkursanforderung von Nasdaq gemäß Nasdaq Listing Rule 5550(a)(2) zu erfüllen und das Delisting-Risiko zu mindern. Das Unternehmen hat bis zum 6. April 2026 Zeit, die Konformität wiederzuerlangen.

Zum 20. Oktober 2025 hatte das Unternehmen 103.591.276 ausstehende Stammaktien (95.998.776 Class A; 7.592.500 Class B). Nach der Konsolidierung gab es ca. 1.035.913 ausstehende Stammaktien (ca. 959.988 Class A; 75.925 Class B), gerundet auf ganze Aktien. Hinweis: Bruchteile werden auf ganze Aktien aufgerundet.

Der Ticker bleibt „WOK“, und die Class A-Aktien handeln nun unter der CUSIP G9767H117. Das genehmigte Kapital wurde auf 10.000.000 USD erhöht, aufgeteilt in 160.000.000 Class A Stammaktien mit Nennwert 0,05 USD und 40.000.000 Class B Stammaktien mit Nennwert 0,05 USD. Aktionäre, die elektronisch gehalten wurden, mussten nichts unternehmen.

مجموعة WORK للأجهزة الطبية (WOK) قامت بدمج أسهمها بنسبة 100:1، اعتباراً من 21 أكتوبر 2025، لتلبية متطلبات سعر العرض الأدنى في ناسداك وفق قاعدة 5550(a)(2) وللتخفيف من مخاطر الإقصاء من الإدراج. لدى الشركة حتى 6 أبريل 2026 لاستعادة الامتثال.

في 20 أكتوبر 2025، كانت الشركة تمتلك 103,591,276 سهماً عاديًا قائمًا (95,998,776 فئة A؛ 7,592,500 فئة B). بعد الدمج، كان هناك نحو 1,035,913 سهماً عادياً قائماً (حوالي 959,988 فئة A؛ 75,925 فئة B)، مع تطبيق التقريب إلى الأسهم الكاملة.

الرمز يظل “WOK”، والأسهم من فئة A تُتداول الآن تحت CUSIP G9767H117. زاد رأس المال المصرح به إلى 10,000,000 دولار أمريكي، مقسمة إلى 160,000,000 سهم عادي من فئة A بقيمة اسمية 0.05 دولار لكل منها و40,000,000 سهم عادي من فئة B بقيمة اسمية 0.05 دولار لكل منها. المساهمون الذين يحملون أسهماً إلكترونياً لم يحتاجوا لاتخاذ أي إجراء.

WORK Medical Technology Group (WOK) 已将其股票实行 100:1 的合并,自 2025 年 10 月 21 日起生效,以满足纳斯达克上市规则 5550(a)(2) 的最低出价价格要求并降低退市风险。公司有直到 2026 年 4 月 6 日的时间重新合规。

截至 2025 年 10 月 20 日,公司已发行普通股总数为 103,591,276 股(A 类 95,998,776 股;B 类 7,592,500 股)。合并后,约有 1,035,913 股普通股在外流通(约 959,988 股 A 类;75,925 股 B 类),对小数股数按整股向上舍入。

代码仍为 “WOK”,A 类股现已在 CUSIP G9767H117 下交易。授权资本增至 10,000,000 美元,分为 1.6 亿股 A 类普通股(面值 US$0.05)和 4,000 万股 B 类普通股(面值 US$0.05)。以电子方式持有的股东无需采取任何行动。

Positive
  • None.
Negative
  • None.

Insights

Reverse split 100:1; share count shrinks, pricing per share adjusts.

WOK executed a 100:1 share consolidation effective October 21, 2025. This reduces the number of shares outstanding while proportionally increasing the per-share price, a standard mechanism aimed at meeting Nasdaq’s minimum bid price requirement under Rule 5550(a)(2).

Pre-split, the company reported 103,591,276 ordinary shares outstanding as of October 20, 2025; post-split that figure is approximately 1,035,913, with fractional shares rounded up. The authorized capital was reset to US$10,000,000 (160,000,000 Class A and 40,000,000 Class B at US$0.05 par).

The compliance window runs until April 6, 2026. Actual market impact depends on trading dynamics and whether the higher post-split bid price sustains at or above Nasdaq’s threshold.

WORK Medical Technology Group (WOK) ha consolidato le proprie azioni 100:1, con effetto dal 21 ottobre 2025, per soddisfare il requisito di prezzo minimo di Nasdaq ai sensi della Nasdaq Listing Rule 5550(a)(2) e mitigare il rischio di delisting. L’azienda ha tempo fino al 6 aprile 2026 per tornare a rispettare le norme.

Al 20 ottobre 2025, la società aveva 103.591.276 azioni ordinarie in circolazione (95.998.776 Classe A; 7.592.500 Classe B). Dopo la consolidazione, vi erano circa 1.035.913 azioni ordinarie in circolazione (circa 959.988 Classe A; 75.925 Classe B), soggette all’arrotondamento delle azioni frazionarie alle azioni intere.

Il ticker rimane “WOK” e le azioni Classe A ora sono negoziate sotto il CUSIP G9767H117. Il capitale autorizzato è aumentato a US$10.000.000, suddiviso in 160.000.000 azioni ordinarie Classe A dal valore nominale di US$0,05 ciascuna e 40.000.000 azioni ordinarie Classe B dal valore nominale di US$0,05 ciascuna. Gli azionisti tenuti in forma elettronica non hanno dovuto intraprendere alcuna azione.

Grupo de Tecnología Médica WORK (WOK) consolidó sus acciones 100:1, con efectos a partir del 21 de octubre de 2025, para cumplir con el requisito de precio mínimo de Nasdaq según la Regla de Listado 5550(a)(2) y mitigar el riesgo de salida de la lista. La empresa tiene hasta el 6 de abril de 2026 para volver a cumplir.

Al 20 de octubre de 2025, la compañía tenía 103.591.276 acciones ordinarias en circulación (95.998.776 Clase A; 7.592.500 Clase B). Después de la consolidación, había aproximadamente 1.035.913 acciones ordinarias en circulación (aproximadamente 959.988 Clase A; 75.925 Clase B), sujeto al redondeo de fracciones a acciones enteras.

El ticker sigue siendo “WOK”, y las acciones Clase A ahora se negocian bajo el CUSIP G9767H117. El capital autorizado aumentó a US$10,000,000, dividido en 160,000,000 de acciones ordinarias Clase A con valor nominal de US$0.05 cada una y 40,000,000 de acciones ordinarias Clase B con valor nominal de US$0.05 cada una. Los accionistas que mantenían electrónicamente no necesitaron tomar ninguna acción.

WORK Medical Technology Group(WOK)가 100:1로 주식 합병을 2025년 10월 21일부로 실행하여 나스닥의 5550(a)(2) 규정에 따른 최저 매매가 요건을 충족하고 상장폐지 위험을 완화했습니다. 회사는 규정을 다시 준수하기 위해 2026년 4월 6일까지의 기간이 있습니다.

2025년 10월 20일 현재 회사의 보통주 발행 주식 수는 103,591,276주였습니다(클래스 A 95,998,776주; 클래스 B 7,592,500주). 합병 후에는 대략 1,035,913주가 발행되어(대략 A 959,988주; B 75,925주), 소수점 주는 정수 주로 반올림될 수 있습니다.

티커는 여전히 “WOK”이며 클래스 A 주식은 이제 CUSIP G9767H117로 거래됩니다. 승인 자본은 미화 1,000만 달러로 증가했으며, 1억6천만 주의 클래스 A 보통주(표면가 US$0.05)와 4천만 주의 클래스 B 보통주(표면가 US$0.05)로 구성됩니다. 전자적으로 보유한 주주들은 아무 조치도 필요하지 않았습니다.

WORK Medical Technology Group (WOK) a consolidé ses actions en 100:1, avec effet au 21 octobre 2025, afin de répondre à l’exigence de prix d’introduction minimum de Nasdaq conformément à la règle Nasdaq Listing 5550(a)(2) et de réduire le risque de radiation. L’entreprise dispose jusqu’au 6 avril 2026 pour retrouver la conformité.

Au 20 octobre 2025, la société comptait 103 591 276 actions ordinaires en circulation (95 998 776 Classe A; 7 592 500 Classe B). Après la consolidation, il y avait environ 1 035 913 actions ordinaires en circulation (environ 959 988 Classe A; 75 925 Classe B), sous réserve de l’arrondi des fractions à des actions entières.

Le symbole boursier demeure «WOK», et les actions Classe A se négocient désormais sous le CUSIP G9767H117. Le capital autorisé a été porté à 10 000 000 USD, réparti en 160 000 000 d’actions ordinaires Classe A d’une valeur nominale de 0,05 USD chacune et 40 000 000 d’actions ordinaires Classe B d’une valeur nominale de 0,05 USD chacune. Les actionnaires détenant électroniquement n’avaient pas besoin d’agir.

WORK Medical Technology Group (WOK) hat seine Aktien im Verhältnis 100:1 zusammengelegt, mit Wirkung zum 21. Oktober 2025, um die Mindestkursanforderung von Nasdaq gemäß Nasdaq Listing Rule 5550(a)(2) zu erfüllen und das Delisting-Risiko zu mindern. Das Unternehmen hat bis zum 6. April 2026 Zeit, die Konformität wiederzuerlangen.

Zum 20. Oktober 2025 hatte das Unternehmen 103.591.276 ausstehende Stammaktien (95.998.776 Class A; 7.592.500 Class B). Nach der Konsolidierung gab es ca. 1.035.913 ausstehende Stammaktien (ca. 959.988 Class A; 75.925 Class B), gerundet auf ganze Aktien. Hinweis: Bruchteile werden auf ganze Aktien aufgerundet.

Der Ticker bleibt „WOK“, und die Class A-Aktien handeln nun unter der CUSIP G9767H117. Das genehmigte Kapital wurde auf 10.000.000 USD erhöht, aufgeteilt in 160.000.000 Class A Stammaktien mit Nennwert 0,05 USD und 40.000.000 Class B Stammaktien mit Nennwert 0,05 USD. Aktionäre, die elektronisch gehalten wurden, mussten nichts unternehmen.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

 

Commission File Number: 001-42256

 

WORK Medical Technology Group LTD

 

Floor 23, No. 2 Tonghuinan Road

Xiaoshan District, Hangzhou City, Zhejiang Province

People’s Republic of China, 241003

(Address of principal executive offices) 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F      Form 40-F 

 

 

 

 

 

Consolidation of Ordinary Shares

 

On September 12, 2025, WORK Medical Technology Group LTD (the “Company”) held an extraordinary general meeting of shareholders (the “EGM”). During the EGM, the shareholders passed certain resolutions with respect to: (i) one or more share consolidations of all of the authorized, issued, and outstanding shares of the Company (collectively, the “Shares”), each at such consolidation ratio and with such effective time as the board of directors of the Company (the “Board”) may determine in its sole discretion (together, the “Share Consolidations,” and each, a “Share Consolidation”); provided, however, that the accumulated consolidation ratio for any and all such Share Consolidations shall be no less than 2:1 nor greater than 250:1, with such consolidated Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of each class as set out in the Company’s existing amended and restated memorandum and articles of association; (ii) an increase in the Company’s authorized share capital from US$250,000 divided into 400,000,000 Class A ordinary shares of par value US$0.0005 each and 100,000,000 Class B ordinary shares of par value US$0.0005 each, to a maximum of US$10,000,000 divided into Class A ordinary shares and Class B ordinary shares, in each case, of the then current par value, as a result of the Share Consolidation(s) at a ratio of four Class A ordinary shares for every one Class B ordinary shares (the “Share Capital Increase”); such Share Capital Increase to be conditional upon approval by the Board, in its sole discretion, and to take effect on such date as the Board may determine, within one year from the date of the EGM; and (iii) the adoption of a further amended and restated memorandum of association to reflect the relevant Share Consolidation and/or the Share Capital Increase.

 

On September 29, 2025, the Board passed certain resolutions with respect to (i) a consolidation of the Shares at the ratio of 100:1; (ii) an increase in the Company’s authorized share capital from US$250,000 divided into 400,000,000 Class A ordinary shares of par value US$0.0005 each and 100,000,000 Class B ordinary shares of par value US$0.0005 each, to US$10,000,000 divided into 160,000,000 Class A ordinary shares of par value US$0.05 each and 40,000,000 Class B ordinary shares of par value US$0.05 each; and (iii) the adoption of an amended and restated memorandum of association in substitution for, and to the entire exclusion of, the Company’s existing memorandum of association, to reflect the Share Consolidation and the Share Capital Increase.

 

Reason for the Share Consolidation. The Share Consolidation was implemented so that the Company can expeditiously meet the continued listing standard of the Nasdaq Stock Market (“Nasdaq”) relating to the minimum bid price under Nasdaq Listing Rule 5550(a)(2), and to mitigate the risk of the Company being delisted from the Nasdaq. The Company has until April 6, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).

 

Effective Date; Symbol; CUSIP Number. The effective date of the Share Consolidation was October 21, 2025 (the “Effective Date”), which was reflected on the Nasdaq marketplace at the opening of business on October 21, 2025, whereupon the Company’s Class A ordinary shares began trading on a post-consolidation basis. The Company’s Class A ordinary shares continue to trade on Nasdaq under the same symbol “WOK” with a new CUSIP Number, G9767H117.

 

Adjustment; No Fractional Shares. On the Effective Date, the number of the Company’s ordinary shares held by each shareholder was converted into the number of ordinary shares held by such shareholder immediately prior to the Share Consolidation divided by one hundred (100), with any resulting fractional shares rounded up to the whole number of shares. 

 

Non-Certificated Shares. Shareholders who hold their ordinary shares in electronic form at brokerage firms did not have to take any action, as the Share Consolidation was automatically reflected in their brokerage accounts.

 

Authorized Shares. On the Effective Date, the Company’s authorized ordinary shares were consolidated at the ratio of one hundred-for-one, and the authorized share capital of the Company became US$10,000,000 divided into 160,000,000 Class A ordinary shares of par value US$0.05 each and 40,000,000 Class B ordinary shares of par value US$0.05 each.

 

Capitalization. As of October 20, 2025, the Company had 103,591,276 ordinary shares issued and outstanding, composed of 95,998,776 Class A ordinary shares and 7,592,500 Class B ordinary shares. As a result of the Share Consolidation, upon the Effective Date, there were approximately 1,035,913 ordinary shares issued and outstanding, composed of approximately 959,988 Class A ordinary shares and 75,925 Class B ordinary shares (subject to the adjustment of rounding fractional shares into additional whole shares).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: October 21, 2025

  

  WORK Medical Technology Group LTD
     
  By: /s/ Shuang Wu
  Name:   Shuang Wu
  Title: Chief Executive Officer

 

 

2

 

FAQ

What did WOK change with its shares on October 21, 2025?

WOK implemented a 100:1 share consolidation effective October 21, 2025, with fractional shares rounded up to the next whole share.

How many WOK shares are outstanding after the consolidation?

Approximately 1,035,913 ordinary shares outstanding, composed of about 959,988 Class A and 75,925 Class B shares.

What were WOK’s shares outstanding before the reverse split?

As of October 20, 2025, WOK had 103,591,276 ordinary shares outstanding (95,998,776 Class A; 7,592,500 Class B).

Why did WOK conduct the share consolidation?

To address Nasdaq Listing Rule 5550(a)(2) minimum bid price and reduce delisting risk. The company has until April 6, 2026 to regain compliance.

Did WOK change its ticker or CUSIP?

The ticker remains WOK. The Class A ordinary shares now trade under new CUSIP G9767H117.

What is WOK’s new authorized share capital?

Authorized capital is US$10,000,000, divided into 160,000,000 Class A and 40,000,000 Class B ordinary shares, each with US$0.05 par value.

Do WOK shareholders need to take action for the split?

No. Holders in electronic brokerage accounts had the consolidation automatically reflected in their accounts.
WORK Medical Technology Group LTD

NASDAQ:WOK

WOK Rankings

WOK Latest News

WOK Latest SEC Filings

WOK Stock Data

2.84M
47.45M
13.56%
0.2%
1.12%
Medical Devices
Healthcare
Link
China
Hangzhou